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ABSTRACT	
Across sub-Saharan Africa, patients with HIV on antiretrovirals often get malaria and need co-treatment with artemisinin-containing therapies. We undertook two pharmacokinetic studies in healthy volunteers, using standard adult doses of artmether-lumefantrine or artesunate-amodiaquine given with 50mg once daily dolutegravir (DTG) to investigate the drug-drug interaction between artmether-lumefantrine or artesunate-amodiaquine and dolutegravir. The dolutegravir/artmether-lumefantrine interaction was evaluated in a two-way cross-over study and measured artemether, dihydroartemisinin, lumefantrine, desbutyl-lumefantrine over 264 hours. The dolutegravir/artesunate-amodiaquine interaction was investigated using a parallel study design due to long half-life of the amodiaquine metabolite, desethylamodiaquine and measured artesunate, amodiaquine, desethylamodiaquine over 624 hours. Non-compartmental analysis was performed, and geometric mean ratios and 90% confidence intervals generated for evaluation of both interactions. Dolutegravir did not significantly change the maximum concentration in plasma, time to maximum concentration and area under the concentration-time curve (AUC) for artemether, dihydroartemisinin, lumefantrine and desbutyl-lumefantrine nor significantly alter AUC for artesunate, dihydroartemisinin, amodiaquine and desethylamodiaquine. Co-administration of dolutegravir with artmether-lumefantrine resulted in a 37% decrease in DTG trough concentrations. Co-administration of dolutegravir with artesunate-amodiaquine resulted in a decrease of approximately 42% and 24% in DTG trough concentrations and AUC respectively. The significant decreases in DTG trough concentrations with artemether-lumefantrine and artesunate-amodiaquine and dolutegravir exposure with artesunate-amodiaquine are unlikely to be of clinical significance as DTG trough concentrations were above dolutegravir target concentrations of 300ng/mL. Study drugs were well-tolerated with no serious adverse events. Standard doses of artemether-lumefantrine and artesunate-amodiaquine should be used in patients receiving dolutegravir.
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INTRODUCTION
Over 90% of  malaria cases occur in sub-Saharan Africa (SSA) the region with the greatest burden of HIV(1). Drug-drug interactions (DDIs) between antiretrovirals and artemisinin-based combination therapies (ACT) frequently occur and may affect the clinical effectiveness of commonly utilized antimalarials artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ)(2-4).The likely adoption of dolutegravir (DTG) in preferred first-line antiretroviral therapy (ART) regimens(4) makes a DDI study with antimalarials an urgent priority. Dolutegravir is predominately metabolized via uridine diphosphate glucuronyl transferase 1A1 (UGT 1A1) with minor input from cytochrome P450 (CYP)-3A4 which suggests minimal DDI potential as a perpetrator drug (5).
Both artemether (ARM) and lumefantrine (LF) are predominantly metabolized via CYP3A4, CYP2B6, CYP2C9 and CYP2C19 to active metabolites dihydroartemisinin (DHA) and desbutyl-lumefantrine (DBL) respectively. Artesunate (AS) is a prodrug and substrate of CYP2A6 and undergoes rapid hydrolysis to DHA while amodiaquine (AQ) is extensively metabolized by CYP 2C8 to its active metabolite, N-desethylamodiaquine (DEAQ)(5,7). Co-administration of artemether-lumefantrine with inducers of CYP3A4 results in significant reductions in artemether and dihydroartemisinin exposures(7). Similarly, clinically significant DDIs with ritonavir-boosted protease inhibitor ART regimens have been reported(8). However, data for dolutegravir interactions with antimalarial therapies are lacking. We investigated the pharmacokinetic (PK) interactions between dolutegravir with artemether-lumefantrine or artesunate-amodiaquine and assessed safety and tolerability of the drug combinations.

METHODS
Ethics: The study was approved by the Joint Clinical Research Centre Institutional Review Board, Kampala, Uganda and University of Liverpool Research Ethics Committee, Liverpool, UK and registered on ClinicalTrials.gov (NCT 02242799). The study was conducted in compliance with International Council for Harmonisation Good Clinical Practice guidelines, the current ethical principles in the Declaration of Helsinki and applicable local regulatory requirements.
Study Design: Two open-label, fixed sequence studies between dolutegravir (Tivicay®; ViiV Healthcare, Research Triangle Park, NC, USA) given at 50mg once daily  and artemether-lumefantrine (Coartem®; Novartis Pharma AG, Basel, Switzerland) (Study A), or artesunate-amodiaquine (Winthrop®; Sanofi-Aventis, Casablanca, Morocco) (Study B) were conducted at the Infectious Diseases Institute, Kampala, Uganda (Figure 1). Inclusion of 16 subjects in Study A was calculated to have a >80% power to detect a change in area under the concentration-time curve (AUC) outside FDA limits for bioequivalence (90% confidence intervals for AUC falling within 80-125%) for dolutegravir and lumefantrine (assuming coefficient of variation ≤30%), and to detect a ≥32% change in dihydroartemisinin levels. Including 30 subjects in Study B would yield an 80% power to detect an AUC difference of >25-30% (DTG and DEAQ), and a ≥42% change for dihydroartemisinin. 
Eligibility Criteria: Consenting healthy adults (≥18 years) weighing above 40 kg, without malaria and HIV were eligible to participate if they were willing to use mosquito bed nets and able to comply with study procedures. Subjects were excluded if they had evidence of significant systemic disease, serum liver transaminases above three times the upper limits of normal, serum creatinine above two times upper limits of normal, positive hepatitis B surface antigen, evidence of QT prolongation on ECG exceeding 450ms (men) or 470ms (women), and were taking medications which are well known inhibitors or inducers of CYPs or glucuronyl transferase UGT1A1. Pregnant or breastfeeding women and female volunteers unwilling to use reliable contraception during the study were also excluded. 
Dosing and Sampling
Study A (Artemether-lumefantrine) 	
Study A used a random sequence two-way crossover study design with participants randomized to Sequence 1 or Sequence 2. In Sequence 1, participants received six doses of oral artemether-lumefantrine tablets (80/480 mg twice daily taken with food) for three days (regimen used for treatment of uncomplicated malaria) with PK sampling at predose (0 h) and at 1,2,3,4,8,12,24,48,72,96,168 and 264 hours after the final dose. After a 21-day washout, selected from the expected terminal half-lives of lumefantrine and desbutyl-lumefantrine, they received dolutegravir 50mg once daily alone for six days with PK sampling on day-6 at predose (0 h) and at 1,2,3,4,8,12 and 24 hours post-dosing. Subsequently they received three days of twice daily AL plus dolutegravir, with PK sampling at predose (0 h) and at 1,2,3,4,8,12,24,48,72,96,168 and 264 hours after the final doses of both drugs using the sampling time points described. In sequence 2, participants received the dolutegravir and DTG-AL combination with PK sampling as detailed for Sequence 1, followed by artemether-lumefantrine alone after the 21-day washout period.
Study B (Artesunate-amodiaquine)
Study B used a parallel group design due to the long terminal half-life of approximately nine to eighteen days for the amodiaquine active metabolite N-desethylamodiaquine. Participants were randomized to receive AS-AQ (4 mg/Kg AS, 10 mg/kg AQ) once daily for three days with PK sampling at predose (0 h) and at 1,2,3,4,8,12,24,48,72,96,120,228 and 624 hours post-last dose (Arm 1), or dolutegravir for seven days with PK sampling at predose (0 h) and at 1,2,3,4,8,12 and 24 hours after the last dose, followed by AS-AQ once daily together with dolutegravir 50mg once daily for three days, with PK sampling after the last dose of both drugs using the sampling time points listed (Arm 2). 
All study drugs prior to intensive PK sampling were administered after an overnight fast. A standard moderate fat breakfast was provided after the pre-dose (0 h) sampling.
Safety assessments
At screening, a medical history, physical examination, urine pregnancy test, rapid malaria and HIV tests and safety bloods (hemoglobin, white cell count, platelets, urea, creatinine, electrolytes, ALT) were performed. A 12-lead ECG was performed at screening, intensive PK and at end of study. Safety bloods were repeated at every intensive PK visit and prior to discharge from the study. Laboratory and clinical abnormalities were graded for severity according to the U.S National Institutes for Health Division of AIDS (DAIDS) Table for Grading Severity of Adult and Pediatric Adverse Events.
Pharmacokinetic analysis
Dolutegravir blood samples were collected in ethylenediaminetetraacetic acid (K2EDTA) coated tubes(9). Samples for artemether/dihydroartemisinin, lumefantrine/desbutyl-lumefantrine, and amodiaquine/desethylamodiaquine were collected in lithium heparin tubes while artesunate/dihydroartemisinin was collected in fluoride-oxalate tubes to minimize ex-vivo degradation of artemisinins to dihydroartemisinin by plasma esterases(10,11). Blood samples were delivered within 15 minutes of collection to the laboratory for separation and storage at -80ºC until shipment to the Liverpool Bioanalytical Facility and Mahidol University for quantification of dolutegravir and ACTs, respectively. Both laboratories participate in external Quality Assurance programmes for antiretrovirals (Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology (KKGT), The Netherlands) and antimalarials (Quality Assurance/Quality Control proficiency testing program supported by the Worldwide Antimalarial Resistance Network) and operate to GCP with assays validated according to published FDA guidelines. 
Dolutegravir was extracted using liquid-liquid extraction and analyzed using a validated reversed phase liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a lower limit of quantification (LLOQ) set at 10 ng/ml and precision of 5% at low QC (30ng/mL)(9). 
Antimalarial drugs were extracted using solid-phase extraction, and quantified by liquid chromatography-tandem mass spectrometry. For artemether and dihydroartemisinin the total-assay coefficients of variation were < 6% with LLOQ of 1.14 ng/ml. For artesunate and dihydroartemisinin the total-assay coefficients of variation were < 7% with LLOQ of 0.119 ng/ml (AS) and 0.196 ng/ml (DHA)(11).  For lumefantrine and desbutyl-lumefantrine total-assay coefficients of variation were <6% with LLOQ of 7.77 ng/ml (LF) and 0.81 ng/ml (DBL)(12). For amodiaquine and N-desethylamodiaquine the total-assay coefficients of variation were <8% with LLOQ of 0.86 ng/ml (AQ) and 1.13 ng/ml (DEAQ). 
Statistical analysis
Pharmacokinetic parameters including the area under the concentration-time curve to the last measurable time point (AUC0-t), terminal elimination half-life (t1/2 ), maximum concentration (Cmax) and time to Cmax (Tmax) were estimated using non-compartmental analysis (WinNonlin, Phoenix, version 6.1, Pharsight, Mountain View, CA). The elimination clearance (CL/F) of parent drug was calculated using the equation Dose/AUC0-t. PK data were log-transformed to calculate geometric mean ratios (GMR), with 90% CI evaluated using paired (Study A) or unpaired (Study B) t-tests and back-transformed to absolute ng/mL concentrations. The changes in PK parameters were considered statistically significant for a drug-drug interaction when the CI did not cross the value of one. An analysis of variance (ANOVA) was performed by SPSS (Windows Standard version 22; SPSS, Inc., Chicago, IL) on PK parameters (AUC0-t, Cmax, C24) using generalized linear models procedures to assess potential sequence and period related effects. 

RESULTS
Forty-eight participants were enrolled into both studies: 18 study A and 30 study B. In study A, two participants withdrew consent and another two were terminated from the study due to non-adherence to study procedures. In study B, one participant was withdrawn due to safety concerns, three participants withdrew consent and one was terminated from the study due to non-adherence to study procedures. Statistical analysis was performed on 39 subjects who completed study procedures and their demographic variables are presented in Table 1. 
Antimalarial Pharmacokinetics 
Effect of dolutegravir on artemether-lumefantrine pharmacokinetics (Study A)
In study A, 14 participants received artemether-lumefantrine (7 sequence 1; 7 sequence 2). The PK profiles for artemether/dihydroartemisinin (0-24 hours), lumefantrine/desbutyl-lumefantrine (0-264 hours), and associated PK parameters are presented in Table 2. 
When given with dolutegravir, artemether Cmax decreased by 13% [GMR (90% Cl), 0.87(0.67, 1.14)] after approximately two hours with a 5% increase in AUC0-t [GMR (90% Cl), 1.05 (0.84, 1.32)]. The active metabolite dihydroartemisinin peak concentrations decreased by 19% [GMR (90% Cl), 0.81 (0.64, 1.03)] after 2.3 hours with a decrease of 8% in AUC0-t [GMR (90% Cl), 0.92 (0.79, 1.07)]. Artemether and dihydroartemisinin were eliminated from plasma with an average half-life of 5 and 2.5 hours, respectively. 
Similarly lumefantrine showed peak concentrations approximately four hours after drug administration, with a 12% increase in Cmax [GMR (90% Cl), 1.12 (0.97, 1.29)] and 10% increase in AUC0-t [GMR (90% Cl), 1.10 (0.96, 1.27)]. The lumefantrine metabolite desbutyl-lumefantrine had a 3% decrease in Cmax [GMR (90% Cl), 0.97 (0.79, 1.18)] and 4% decrease in AUC0-t [GMR (90% Cl), 0.96 (0.80, 1.15)] representing approximately 1.7% of total circulating lumefantrine. Both lumefantrine and desbutyl-lumefantrine had prolonged mean elimination half-lives of approximately 83 and 142 hours, respectively. 

The GMR for each antimalarial and metabolite are presented in Table 2. Co-administration of artemether-lumefantrine with dolutegravir did not significantly alter Cmax, AUC0-t or clearance of artemether, lumefantrine or their metabolites. Furthermore, the time of the last measurable concentration (t) for all artemether-lumefantrine components did not significantly differ when administered alone or in combination with DTG. Interestingly, the terminal elimination half-life of artemether was increased in combination with DTG [GMR (90% Cl), 1.57 (1.09, 2.27)], but this appeared to be largely driven by two subjects who had detectable artemether levels beyond 24 hours in combined phase. The analysis of variance (ANOVA) showed no evidence of a significant sequence or period effect upon artemether-lumefantrine PK.  

Effect of dolutegravir on artesunate-amodiaquine pharmacokinetics (Study B)
In study B, 25 participants received artesunate-amodiaquine. Thirteen subjects in Arm 1 were administered artesunate-amodiaquine alone, and 12 subjects in Arm 2 were administered artesunate-amodiaquine with dolutegravir. The PK profiles for artesunate/ dihydroartemisinin (0-12 hours), amodiaquine/N-desethylamodiaquine (0-624 hours), and associated PK parameters are presented in Table 2. 
When given with dolutegravir, artesunate maximum concentrations reduced by 15% [GMR (90% Cl), 0.85 (0.56, 1.28)] within 1.2 hours, with an overall decrease in AUC0-t of 10% [GMR (90% Cl), 0.90 (0.59, 1.37)] compared with artesunate-amodiaquine alone. Dihydroartemisinin exposures were on average 6-fold higher than corresponding artesunate AUC0-t values. Artesunate and dihydroartemisinin geometric mean half-life was 1.9 and 2.2 hours, respectively. Similarly, amodiaquine was rapidly absorbed (Tmax = 2.4 hours) and was detectable in plasma for approximately 70 hours post-dose; overall amodiaquine AUC0-t was 256.1 ng.h/ml (222.5-289.8). Amodiaquine was rapidly and extensively converted to N-desethylamodiaquine (Tmax = 2.7 hours); N-desethylamodiaquine exposures were approximately 122-fold higher than amodiaquine, and persisted in plasma for up to 624 hours post-dose (terminal elimination half-life ~9 to 18 days). Co-administration of dolutegravir with artesunate-amodiaquine did not significantly alter the AUC0-t for artesunate [GMR (90% CI) 0.90; (0.59, 1.37)], dihydroartemisinin [GMR (90% CI) 1.20; (0.89, 1.62)], amodiaquine [GMR (90% CI) 0.88; (0.72, 1.07)] or N-desethylamodiaquine [GMR (90% CI) 0.86; (0.70, 1.05)].

Dolutegravir pharmacokinetics 
Dolutegravir was administered with and without antimalarials to 14 participants in study A (7 sequence 1; 7 sequence 2) and 12 participants in study B (Arm 2). Pooled dolutegravir and antimalarial concentration-time profiles (means plus standard deviations) from 0-24 hours for study A and B are depicted in Figure 2 and Figure 3 respectively.

Effect of artemether-lumefantrine on dolutegravir pharmacokinetics (Study A)
In study A, dolutegravir Cmax increased by 4% [GMR (90% Cl), 1.04 (0.92, 1.18)] approximately 3.9 hours post-dose, with an overall AUC0-24 decrease of 6% [GMR (90% Cl), 0.94 (0.86, 1.02)] compared with steady state dolutegravir alone. Co-administration of dolutegravir with artemether-lumefantrine resulted in a 37% decrease in dolutegravir C24 [GMR (90% Cl), 0.63 (0.48-0.82)]. No significant changes were observed in dolutegravir AUC0-24 or Cmax when dolutegravir was administered with artemether-lumefantrine (Table 2). The ANOVA revealed no significant sequence effect upon dolutegravir PK. Furthermore, there was no significant period effect (DTG alone vs. DTG + AL) for dolutegravir C24 in both arms.

Effect of artesunate-amodiaquine on dolutegravir pharmacokinetics (Study B)
In study B, dolutegravir Cmax decreased by 9% [GMR (90% Cl), 0.91 (0.80, 1.04)] approximately 3.7 hours post-dose, with an overall AUC0-24 decrease of 24% [GMR (90% Cl), 0.76 (0.69, 0.84)]. Co-administration of dolutegravir with artesunate-amodiaquine resulted in a significant decrease of approximately 42% and 24% in dolutegravir C24 and AUC0-24, respectively as presented in Table 2.


Safety
No deaths or serious adverse events (SAEs) were reported during the study.  In total, 111 adverse events (AEs) were observed and reported with 80 AEs judged as having a temporal relationship with study medication. All adverse events were Grade 1 or 2 in severity. Gastro-intestinal adverse events were more frequent among participants receiving artesunate-amodiaquine. No clinically significant changes were observed during safety assessments (laboratory blood assessments, ECG or vital signs).


DISCUSSION 
This is the first study to examine for drug interactions between dolutegravir with artemether-lumefantrine and artesunate-amodiaquine. We found no significant impact of dolutegravir upon drug exposure of either antimalarial regimen, suggesting that standard doses of artemether-lumefantrine and artesunate-amodiaquine should be used when co-administered with dolutegravir. These findings are important given the increasing use of dolutegravir in first-line antiretroviral therapy regimens. The results confirm the low propensity for dolutegravir to perpetrate clinically significant DDIs, as judged by in-vitro observations of minimal effects on drug transporters and cytochrome P450 enzymes(6,12).

We observed that artemether-lumefantrine was not associated with any significant change in dolutegravir exposure parameters (Cmax, AUC0-24). However, dolutegravir C24 was 37% lower with artemether-lumefantrine than when given alone. The reasons for this are unclear but may have been driven in part by an unexplained rise in dolutegravir C24 in some participants. Additional intake of dolutegravir prior to the last sampling point at 24 hours was unlikely, as subjects were instructed not to take the next dose before this time-point, and were issued with an exact number of pills which precluded such additional intake.

With artesunate-amodiaquine, we observed an unexplained statistically significant reduction of 42% and 24% for dolutegravir C24 and AUC0-24 respectively. However, in all subjects who received DTG with artemether-lumefantrine or artesunate-amodiaquine, the dolutegravir Ctrough was comparable to or above 1100ng/mL(14), the mean Ctrough observed in prior dolutegravir phase 3 adults trials. The target minimum effective concentrations for dolutegravir are unknown, although a DTG protein-adjusted effective concentration (EC90) above 300ng/mL has been proposed(15,16). In a phase II study, Ctrough concentrations over 324ng/mL after 10 days of DTG monotherapy were associated with virological efficacy(13). All subjects in our study had Ctrough concentrations exceeding these targets, suggesting that the modest pharmacokinetic changes observed have unlikely clinical significance, especially given the short duration of antimalarial therapy. 

Notably, dolutegravir concentrations in this study of black African healthy volunteers were somewhat higher than previously reported in Caucasians where exposures of 4560 ng/mL and 7080 ng.h/mL for Cmax and AUC0-t respectively were observed(15). However, it should be noted that in our study, dolutegravir was dosed with a moderate fat meal, and concentrations observed are consistent with reports on the food effect upon DTG bioavailability(17). 

We observed a 65% increase in time to reach maximum concentration (Tmax) for lumefantrine [GMR (90% CI) 1.65; (1.02, 2.69)] and a threefold increase in Tmax for desbutyl-lumefantrine [GMR (90% CI) 3.00; (2.06, 4.36)] during dolutegravir/artemether-lumefantrine coadministration. The reasons for the increase in Tmax for lumefantrine and desbutyl-lumefantrine are unclear, but the observed differences are very unlikely to be clinically significant.

This intensive pharmacokinetic study evaluated the drug-drug interactions using a two-way crossover study design with a 21-day washout period and a parallel study design for dolutegravir/artemether-lumefantrine and dolutegravir/artesunate-amodiaquine respectively. Whilst a cross-over study design would be theoretically ideal for investigating both artemisinin containing therapies in combination with dolutegravir, the amodiaquine active metabolite N-desethylamodiaquine, has an extensive terminal half-life of approximately nine to eighteen days; therefore it was not feasible to undertake a cross-over design for this arm of the study since the washout period between the two phases would exceed two months, risking subject attrition. Furthermore the crossover study design was chosen to allow for a two-way analysis for potential drug interactions between dolutegravir and artemether-lumefantrine. However, the elimination half-life for lumefantrine active metabolite desbutyl-lumefantrine was unexpectedly increased to approximately 142 hours suggesting that the washout period for desbutyl-lumefantrine may not have been sufficiently long. Although this finding highlights a limitation in our study, the analysis of variance found no period or sequence effects upon artemether-lumefantrine pharmacokinetics.

Dolutegravir is a weak inhibitor of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion (MATE) 1 transporter with reported interactions with substrates of both transporters. However, neither lumefantrine nor desbutyl-lumefantrine are substrates of OCT2 and MATE1. It remains unclear by which mechanism dolutegravir might have influenced the observed lumefantrine/desbutyl-lumefantrine pharmacokinetics.

The combination of dolutegravir with artemether-lumefantrine and artesunate-amodiaquine was well tolerated. Nausea, the most common study drug-related adverse event, was reported predominately in the artesunate-amodiaquine arm. This safety profile was consistent with the approved drug labelling (17,18,19). 
 
In conclusion, standard treatment regimens of artesunate-amodiaquine, and of artemether-lumefantrine should be prescribed when treating malaria in HIV-infected patients receiving a dolutegravir based antiretroviral regimen. 
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Figure 1. Study design. Two intensive pharmacokinetic (PK) studies using standard treatment doses of artemether-lumefantrine and artesunate-amodiaquine with 50 mg dolutegravir once daily. 
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